Although both the antiapoptotic function of survivin and vitamin D 3 (VD3)-mediated cell growth inhibition and apoptosis have been extensively studied, it is not known whether survivin plays a role in VD3 compound-mediated cell growth inhibition and apoptosis induction. Using an isogenic model of MCF-7 breast adenocarcinoma cells (MCF-7E and MCF-7L sublines that are sensitive and resistant to VD3 compounds), we found that VD3 compounds effectively downregulated survivin in VD3-sensitive MCF-7E cells, which was associated with VD3-induced apoptosis. In contrast, VD3 compounds failed to downregulate survivin in VD3-resistant MCF-7L cells, which showed resistant to VD3-induced apoptosis. However, inhibition of survivin expression by small interfering RNA (siRNA) induced cell death per se and further sensitized VD3-induced apoptosis in MCF-7L cells, indicating that the inability of these cells to respond to VD3 is due to the failure to downregulate survivin. Forced expression of survivin not only blocked VD3-mediated G1 cell accumulation but also increased S and G2/M cell populations. VD3 treatment rapidly triggered the activation of p38 MAPK signaling in MCF-7E cells but not in MCF-7L cells. Moreover, inhibition of p38 activation diminished VD3-mediated survivin inhibition and partially rescued VD3-induced cell death. We further showed that VD3 increased the expression of TGFb1 and TGFb receptor 2, and that blocking the function of TGFb receptor 2 diminished VD3 compound-mediated survivin downregulation. Thus, we propose that the VD3 compound-induced growth inhibition and apoptosis induction are at least partially dependent on survivin downregulation via VD3-induced TGFb signaling and the activation of p38 MAPK pathway. Targeting survivin through these pathways may lead to novel applications for cancer therapeutics.
Introduction
A new protein family, designated inhibitors of apoptosis (IAP), was recently recognized (Deveraux and Salvesen and Duckett, 2002) . All IAP family members share one or more signature motifs termed the baculovirus IAP repeat (BIR). This zinc-binding motif consists of a conserved sequence of about 70 amino acids. Eight human IAP family members have been identified so far. They are c-IAP1, c-IAP2 (Rothe et al., 1995) , XIAP (Duckett et al., 1996) , NAIP (Roy et al., 1995; Liston et al., 1996) , survivin (Ambrosini et al., 1997) , apollon (Chen et al., 1999) , ML-IAP/livin (Vucic et al., 2000; Kasof and Gomes, 2001 ) and ILP-2 (Richter et al., 2001) . Survivin is a unique member in this family as it has a number of distinct features that it does not share with other members. Survivin is the smallest IAP member (Ambrosini et al., 1997) and is homodimerized in solution (Chantalat et al., 2000; Muchmore et al., 2000; Verdecia et al., 2000) ; it is undetectable in most normal adult tissues but highly expressed in human cancers (Li, 2003) ; expression of survivin is cell cycle-regulated with a robust increase in G2/M phase ; and survivin appears to be involved in both inhibition of apoptosis and regulation of cell division (Li et al., , 1999 Reed and Reed, 1999; Li, 2003) while other IAP members are restricted to one of these two functions (Deveraux and Reed, 1999; Salvesen and Duckett, 2002) .
It has been demonstrated by many studies in multiple systems that modulation of survivin expression or function triggers programmed cell death (apoptosis) (Li, 2003) . The accumulated data from survivin studies on human cancers suggest that survivin expression in cancer is associated with cancer progression, poor prognosis, drug resistance, and shorter patient survival (Li, 2003) . In vitro and in vivo studies targeting survivin with antisense oligonucleotides (Li et al., 1999; Chen et al., 2000; Olie et al., 2000; Xia et al., 2002) , dominant-negative mutants (Li et al., , 1999 Grossman et al., 1999a, b; O'Connor et al., 2000; Mesri et al., 2001) , ribozymes (Pennati et al., 2002; Choi et al., 2003) , triplex DNA-formation (Shen et al., 2003) and RNA interference (Ling and Li, 2004) have shown induction of apoptosis, reduction of tumorgrowth potential, and sensitization to chemotherapeutic drugs and other therapeutic approaches . These studies indicate that survivin is an excellent novel target for cancer therapeutics.
Vitamin D 3 (VD3) compounds have been demonstrated to be effective for inhibition of cell proliferation and induction of apoptosis in vitro and in vivo in a variety of cancer cell models (Colston et al., 1992; Peehl et al., 1994; Simboli-Campbell et al., 1996; Getzenberg et al., 1997) . They are currently in clinical trials for cancer therapeutics (Hansen et al., 2000; Johnson et al., 2002) . However, the mechanisms by which these compounds generate inhibition of proliferation and induction of apoptosis in tumor cells are not fully understood. The inhibition of cell proliferation mediated by VD3 compounds has been reported to be due to modulation of cell cycle regulators and a G1 phase arrest through induction of p21 and p27 in pancreatic and breast cancer cells (Kawa et al., 1997; Wu et al., 1997; Verlinden et al., 1998) . However, another report showed that VD3-induced G1 arrest is associated with a significant decrease of p21 and increase of p27 in squamous cell carcinoma cells (Hershberger et al., 1999) . The contextuality of these studies in different cancer cell types suggests that inhibition of proliferation by VD3 compounds may involve several pathways. VD3 compounds have also been shown to induce apoptosis in a variety of cancers including breast cancer (James et al., 1996 (James et al., , 1998 , colon cancer (Diaz et al., 2000) , and prostate cancer (Blutt et al., 2000) . Although the apoptosis induced by VD3 compounds is characterized by genomic DNA fragmentation (James et al., 1998; Blutt et al., 2000) , caspase activation and poly(ADP-ribose) polymerase (PARP) cleavage (Johnson et al., 2002) , the mechanism by which these events happen is not very clear. For example, it was shown that Bcl-2 expression could be positively or negatively regulated by VD3 compounds, but not essential for apoptosis (Diaz et al., 2000) . These results suggest that other factors or targets rather than Bcl-2 may be involved in the VD3 compound-induced growth inhibition and apoptosis.
It was reported that VD3 and its analog EB1089 inhibit the MCF-7E subline growth by induction of transforming growth factor b receptor II (TGFbRII) (Wu et al., 1998) and TGFb isoforms (Yang et al., 2001) . In contrast, proliferation of the MCF-7L isogenic subline, which has lost cell surface RII and is resistant to TGFb, was not affected by these compounds (Wu et al., 1998) . However, the downstream targets controlling these differential responses to VD3 compounds in these cells are not well defined. In the present study, we report that VD3-sensitive MCF-7E breast cancer cells express a low basal level of survivin that is sensitive to downregulation by VD3 compound treatment. VD3-mediated inhibition of survivin expression in MCF-7E cells evoked apoptosis. In contrast, VD3-resistant MCF-7L breast cancer cells express a high basal level of survivin that is not sensitive to inhibition by VD3 compounds, resulting in resistance to apoptosis. Our data further indicated that VD3-mediated survivin repression is p38 MAPK activation and TGFb signaling-dependent. Thus, our studies, for the first time, demonstrate that VD3-induced apoptosis is at least in part due to TGFb and p38 signaling-dependent downregulation of survivin expression.
Targeting survivin through these pathways may lead to novel applications for cancer treatment.
Results

Differential expression of survivin in MCF-7E and MCF-7L breast cancer cells
It has been shown that MCF-7E cells are sensitive to VD3 compounds while MCF-7L cells are resistant to these agents (Wu et al., 1998) . Accordingly, Western blot experiments revealed that the basal level of survivin expression in MCF-7E cells is lower than that in MCF-7L cells (Figure 1a ). Northern blot experiments showed that the differential expression of survivin protein is accompanied by a differential expression of survivin mRNA (Figure 1b ). 
Downregulation of survivin by VD3 is also essential for VD3-mediated cell growth inhibition
Using a survivin siRNA approach we have provided direct evidence indicating that downregulation of survivin is essential for VD3-induced apoptosis ( Figure 4 ). Further experiments indicated that VD3-induced survivin downregulation is also essential for VD3-mediated growth arrest. As shown in Figure 5 , forced expression of survivin in MCF-7E cells not only blocked the accumulation of G1 cells but also increased S and G2/M cell populations in comparison with the empty vector-transfected cell control treated with VD3. These results demonstrated an essential role of survivin in VD3-mediated cell growth inhibition and apoptosis induction (Figures 4 and 5) .
MCF-7E cells
MCF-7L cells
Survivin - 
MCF-7E cells
MCF-7L cells
Downregulation of survivin expression by VD3 compounds and growth factor deprivation is associated with increased p38 MAPK phosphorylation in MCF-7E cells
To delineate the potential mechanism by which VD3 compounds and growth factor withdrawal downregulated survivin expression, MCF-7E and 7L cells were treated with VD3 or subjected to growth factor deprivation, followed by Western blots to probe phosphorylation of p38 MAPK. The results showed that both VD3 and growth factor deprivation activate p38 as reflected by the increased signal of the p38 phosphorylation ( Figure 7a and b). In contrast, p38 phosphorylation in MCF-7L cells was not increased by either VD3 treatment or growth factor deprivation ( Figure 7c and d). This is paralleled by the lack of inhibitory effects by VD3 treatment and growth factor deprivation on survivin expression in MCF-7L cells but not in MCF-7E cells (Figures 2b, c and 6a, b) , suggesting that p38 activation may mediate inhibition of survivin expression in MCF-7E cells. The requirement of p38 phosphorylation for survivin downregulation was further supported by the fact that inhibition of p38 activation by the p38 inhibitor (PD169316) reversed survivin downregulation induced by VD3 ( Figure 8a ) and growth factor withdrawal ( Figure 8b ). Moreover, inhibition of p38 activation also partially rescued VD3-induced cell death (Figure8a, bottom), which further confirmed the involvement of p38 activation in VD3-induced apoptosis.
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Downregulation of survivin by VD3 compounds is partially TGFb signaling-dependent
It has been demonstrated that the autocrine TGFb induced by VD3 analogs in MCF-7E cells is required for inhibition of cell growth and induction of apoptosis (Wu et al., 1998; Yang et al., 2001) . Our data also showed that VD3 increased the expression of TGFb1 and TGFb receptor 2 in MCF-7E cells ( Figure 9 ). We hypothesized that if TGFb signaling is involved in VD3-mediated downregulation of survivin, then abrogating the function of TGFb receptor 2 should diminish the degree of VD3-mediated survivin downregulation. Consistent with this hypothesis, using a Tet-Off-controlled expression of a dominant-negative TGFb receptor 2 to counter against the function of endogenous wild-type TGFb Role of survivin in vitamin D 3 -mediated apoptosisreceptor 2 in MCF-7E cells (MCF7E-DNRII cells) (Ko et al., 1998b) , we found that while survivin expression in the parental MCF-7E cells was not affected by doxycycline (DOX) (Figure 10a , a control), VD3 compounds (EB1089) were able to activate maximal inhibitory effects on survivin expression only when turning the expression of a dominant-negative TGFb receptor 2 (DNRII) off by adding DOX (Figure 10b , lane 3). However, turning expression of a dominantnegative TGFb receptor 2 on in the absence of DOX diminished the effect of VD3 analog, EB1089 on survivin downregulation (Figure 10b , lane 4). These results suggest that the VD3 compound-induced TGFb signaling was involved (refer to the Figure 10 legend for more information). Moreover, the requirement of TGFb and TGFb receptor 2 signaling in downregulation of survivin was further supported by the fact that TGFb1 treatment downregulated survivin expression in MCF-7E cells but not in MCF-7L cells (Figure 11a and b) .
Discussion
It is known that modulation of the expression of survivin, a novel inhibitor of apoptosis (IAP) protein, is associated with cancer cell viability (Li, 2003) , and that VD3 compounds, which are currently in clinical trials, are effective for cancer cell growth inhibition and apoptosis induction (Johnson et al., 2002) . However, it is not known whether survivin is a target in VD3-induced growth inhibition and apoptosis. In this report, Figure 8 Inhibition of p38 activation blocked survivin downregulation induced by VD3 and growth factor deprivation, and partially rescued VD3-induced cell death. MCF-7E cells were treated with or without VD3 (a) or growth factor deprivation (b) in the presence and absence of the p38 inhibitor PD169316. Cells were lysed, and survivin expression was determined by Western bloting. The relative level of survivin expression is indicated after normalization to the b-actin protein internal control. VD3 induced cell death determined by trypan blue exclusion in various conditions in '(a)' was labeled at the bottom (variation is less than 15%) β-Actin-β-Actin- . This observation strongly suggested that VD3 compound-mediated downregulation of survivin is also involved in a TGFb signal-independent pathway. It is unclear whether the p38 activation represents the TGFb signal-independent pathway. Nevertheless, the involvement of TGFb signaling in VD3-mediated survivin downregulation was directly supported by the fact that VD3 increased the expression of TGFb1 and TGFb receptor 2 (Figure 9 ), and exogenous TGFb1 treatment downregulated survivin expression in VD3-sensitive MCF-7E cells but not in VD3-resistent MCF-7L cells (Figure 11) .
We have shown, in this paper, that the basal level of survivin expression is higher in MCF-7L cells than that in MCF-7E cells (Figure 1) , and growth factor deprivation downregulates survivin expression in MCF-7E cells but not in MCF-7L cells ( Figure 5 ). We hypothesized that the cell survival signaling may be higher and deregulated in MCF-7L cells in comparison with that in MCF-7E cells. We have examined both the Akt pathway and the Erk1/2 MAPK pathway in MCF-7E and MCF-7L cells. We found that a low level PI3K/Akt activation can be observed with and without growth factor deprivation in MCF-7L cells. However, the Akt phosphorylation state rapidly became undetectable during growth factor deprivation in MCF-7E cells. Interestingly, we did not find significant Erk1/2 activation, with or without serum starvation, in both MCF-7E and MCF-7L cells.
Previous studies demonstrated that autocrine TGFb signaling mediates VD3 compound-induced growth inhibition and apoptosis in several breast cancer cells including MCF-7E cells (Wu et al., 1998; Yang et al., 2001) . TGFb signals through two TGFb receptors, type I and type II receptors, which are transmembrane serine/ threonine kinases, to activate Smad signaling (Hu et al., 1998) . The later interacts with certain transcription cofactors, and binds to the TGFb/Smad responsive element to turn on the transcription of TGFb target genes (Padgett, 1999) . Interestingly, here, we found that activation of TGFb signaling by VD3 treatment or by the addition of exogenous TGFb1 repressed survivin expression. This finding supports the growing evidence that TGFb signaling through activating Smads may also mediate repression of transcription (Attisano and Wrana, 2000) . In consideration of the important role of survivin in cancer progression, further delineation of the detailed molecular events involved in the potential Smad-mediated repression of survivin transcription will We also showed in this report that VD3 compoundmediated downregulation of survivin required p38 MAPK activation as well. It is currently unclear whether p38 activation is downstream of TGFb signaling or is independent of TGFb signaling in this system. However, it was previously shown that TGFb treatment rapidly activated p38 MAPK in human Burkitt lymphoma B cells (Schrantz et al., 2001) , mammary epithelial cells (Yu et al., 2002) , murine hepatocytes (Yoo et al., 2003) and PC-3U prostate cancer cells (Edlund et al., 2003) . Although these studies showed that the activation of p38 is required for TGFb-mediated apoptosis, the downstream target of p38 activation was not clear. In this report, we demonstrated that activation of p38 by VD3 is required for downregulation of survivin. While the underlying mechanism for the activated p38 to downregulate survivin is currently not clear, two possible mechanisms may be responsible for the p38-mediated downregulation of survivin. First, the activated p38 may phosphorylate certain transcription factor(s) responsible for survivin transcription, since VD3 compounds indeed downregulated survivin mRNA expression (Figure 3) . The other possibility is that activated p38 may directly destabilize survivin protein by phosphorylation. These possibilities remain to be investigated. Regardless of the mechanism, in consistence with the finding that TGFbmediated apoptosis requires p38 activation, our data indicated that inhibition of p38 activation blocks survivin downregulation by VD3 and partially rescued VD3-induced cell death (Figure 8a ).
In addition, although we have shown in this report that VD3 compounds induced caspase activation and PARP cleavage (Figure 4c) , it has been reported that apoptosis induced by VD3 compounds could also be involved in caspase-independent pathway (Mathiasen et al., 1999; Narvaez and Welsh, 2001) . Consistent with these reports, it has been shown that apoptotic cell death triggered by downregulation of survivin could also be involved in both caspase-dependent and caspase-independent pathways (Shankar et al., 2001; Li, 2003; Liu et al., 2004) .
In summary, we have demonstrated, for the first time, that survivin plays an essential role in VD3 compoundinduced cell growth inhibition and apoptosis induction in breast cancer cells. Downregulation of survivin by VD3 compounds is involved in autocrine TGFb signaling and p38 MAPK activation. Targeting survivin by these pathways may lead to novel applications for cancer therapeutics.
Materials and methods
Cell culture and reagents
MCF-7E cells designate the early passages (less than 200 passages) of the MCF-7 breast cancer cell line while MCF-7L cells are from the later passages (more than 500 passages) of MCF-7 breast cancer cells. MCF-7E cells are sensitive to growth inhibition by TGFb or VD3 treatment while MCF-7L cells are resistant to both of these agents (Ko et al., 1998a) . These cells were maintained in DMEM, supplemented with 10% fetal bovine serum (Mediatech Cellgro, Herndon, VA, USA) and penicillin (100 U/ml)/streptomycin (0.1 mg/ml) (Invitrogen, Grand Island, NY, USA) in a humidified incubator with 5% CO 2 at 371C. The genetically modified MCF-7E cells (MCF7E-DNRII) (Ko et al., 1998b) were normally cultured in the same medium above in the presence of G418 (300-500 mg/ ml) and DOX (2 mg/ml). Cells were routinely subcultured twice weekly. VD3 compounds (1a,25(OH) 2 D 3 , EB1089 and CB1093) were provided from Leo Pharmaceutical Products (Ballerup, Denmark). The antibodies for survivin (FL-142), TGFb1 (V) and TGFb receptor 2 (L-21) were purchased from Santa Cruz (Santa Cruz, CA, USA). PD169316 was purchased from CalBiochem (La Jolla, CA, USA). Phospho-p38 MAP kinase (Thr180/Tyr182) antibody and anti-p38 antibody were purchased from Cell Signaling (Beverly, MA, USA). DOX and G418 were purchased from BD Biosciences (San Diego, CA, USA). Propidium iodide (PI), TGFb1, phosphatase inhibitor cocktail 1, monoclonal antiactin antibody and goat peroxidase-conjugated anti-rabbit IgG antibody were purchased from Sigma (St Louis, MO, USA). Lipofectaminet 2000 reagents were purchased from Invitrogen (Carlsbad, CA, USA).
Treatment and Western blot
In all experiments, cells were treated with vitamin D 3 (1a,25(OH) 2 D 3 ) and/or its analogs (EB1089 and CB1093) in medium containing 10% serum. For Western blots, cells were washed with phosphate-buffered saline (PBS) and lysed at 41C for 30 min in PBS containing 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 10 mg/ml phenylmethyl sulfonyl fluoride, and 20 mM leupeptin with or without the phosphatase inhibitor cocktail 1. Cell extracts were cleared by centrifugation at 15 000 g for 20 min at 41. In total, 50 mg total proteins from each sample were heated at 951C for 5 min after mixing with equal volume of 2 Â SDS loading buffer. Samples were separated on 15% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gels and electrotransferred to Immobilon-P membranes (Millipore, Bedford, MA, USA). The membrane was blocked in 5% skim milk or BSA (for phospho-specific antibodies) in TBS-T buffer (20 mM Tris/HCl (pH 7.5), 0.137 M NaCl, and 0.05% Tween-20) at room temperature for 2-3 h. The membranes were incubated with different primary antibodies in TBS-T overnight at 41C in the range of dilutions from 1 : 500 to 1 : 2000. After washing with TBS-T, the membrane was incubated in 5% skim milk in TBS-T buffer containing a secondary antibody (1 : 5000), for 45-60 min at room temperature with shaking. Proteins of interest were detected by an ECL protein detection kit (Amersham, Arlington Heights, IL, USA) and visualized by autoradiography after various times (20-120 s) of exposure. For normalization of protein loading, the same membranes were stripped with stripping buffer (100 mM 2-mercaptoethanol, 2% sodium dodecyl sulphate, 62.5 mM Tris-HCl pH 6.7) and used for Western blot with a monoclonal antibody against actin at a dilution of 1 : 1000 by the same procedure.
Total RNA isolation and Northern blot
Cells in 60 Â 15 mm culture dishes were washed with ice cold PBS and directly lysed in the dish with 1 ml TRI REAGENT (Molecular Research Center, Cincinnati, OH, USA), The lysate was transferred into a 1.5 ml tube and stored at room temperature for 5 min. In total, 0.2 ml chloroform was added to each tube and vortexed vigorously for 15-20 s. After incubation for 2-15 min at room temperature, the samples in the tube were centrifuged at 12 000 r.p.m. for 15 min at 41C. The supernatant containing total RNAs was transferred into a new 1.5 ml RNase-free tube and total RNAs were precipitated with 0.5 ml isopropanol by centrifugation at 12 000 r.p.m. for 10 min at 41C. After washing with 75% ethanol and drying at room temperature for 10 min, the total RNA pellets were resuspended in 15-ml depc-dH 2 O by vortexing and RNA concentrations were determined by spectrophotometer. For Northern blot analysis, 10 mg of total RNAs were diluted in MOPS/formaldehyde/formamide buffer and separated on 1% formaldehyde-denatured agarose gels. The separated RNA was transferred onto Immobilon-N membrane (Millipore, Bedford, MA, USA) and crosslinked by ultraviolet (Stratagene, La Jolla, CA, USA). The membrane was then hybridized with a 32 P-labeled survivin cDNA probe in ExpressHyb hybridization solution (Clontech) for 1 h at 681C. The expression level of survivin mRNA was visualized by autoradiography after washing. The membrane was stripped in 0.1 Â SSC solution and re-hybridized with a 32 P-labeled glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA probe for an internal control.
Trypan blue exclusion staining for determination of cell viability
Cells to be counted were collected by trypsinization/centrifugation and resuspended in PBS buffer. A small sample of the cell suspension was diluted in 0.4% (w/v) trypan blue (one sample a time since viable cells absorb trypan blue over time as well). A cover glass was centered over the hemacytometer chambers and one chamber was filled with the cell dilution using a Pasteur pipette. Stained (dead) and unstained (viable) cells were counted in each of the four corner and central squares under an inverted microscope using 100 Â magnification, respectively. Each cell sample was counted in this way for three times. The percentage of cell viabilities in each sample was calculated with the formula of '% viability ¼ total viable cell numbers/total cell numbers Â 100'. GCA GUG GAU GAA GCC AGC C 120 TT (reverse chain)] were chemically synthesized and purified by HPLC (Xeragon, Huntsville, AL, USA). Equal moles of each RNA oligonucleotide were mixed together to a final concentration of 20 mM in annealing buffer (100 mM KAc, 30 mM HEPES-KOH, 2 mM MgAc 2 , pH 7.4). After denaturation at 901C for 1 min, the survivin siRNA mixture (designated SRi-3) was annealed at 371C for 60 min and stored at À801C for transfection experiments. A scramble RNA duplex (designated scraSRi) was also prepared as above for a negative control in this study. The scramble sequence [5 0 CAG UCG CGU UUG CGA CUG GTT (forward chain) and 5 0 CCA GUC GCA AAC GCG ACU GTT (reverse chain)] was not present in mammalian cells by BLAST search at NCBI. The effectiveness of survivin SRi-3 on survivin inhibition was 75-90% and confirmed in HeLa (Ling and Li, 2004) and MCF-7 cells (Figure 4b, upper panel) .
Transfection of siRNA and cell viability analysis
One day prior to transfection, 3 Â 10 5 cells per well were seeded in six-well plate containing culture medium without antibiotics. Cells at 40-60% confluence were transfected with the scramble (scraSRi) and survivin (SRi-3) siRNAs, respectively, as follows. Serum-free DMEM (100 ml) containing 3 mg siRNAs were mixed with 100 ml serum-free DMEM containing 9 ml Lipofectaminet 2000 reagents and held at room temperature. After the medium in a six-well plate was replaced by serum-free DMEM (800 ml/well), the siRNA-Lipofectaminet 2000 mixture prepared above was added onto each well in the six-well plate within 20-45 min after the mixture was prepared. In total, 330 ml DMEM containing 30% fetal bovine serum was added into each well in the plate 2-4 h later. The transfected cells were treated with and without VD3 16 h post-transfection. Survivin expression was analysed by Western blots and cell viability was analysed microscopically 48 h after VD3 treatment by trypan blue exclusion as described above.
Survivin expression vector transfection and cell cycle analysis
For the transfection of expression vectors, pEGFPc1 control vector and pEGFPc1-survivin expression vector were transfected into MCF-7E cells same as above. The transfected cells were treated with VD3 16 h post-transfection and analysed by PI staining and cell flow cytometry through gating the transfected green cells 24 h after VD3 treatment.
Abbreviations IAP, inhibitor of apoptosis; BIR, baculovirus IAP repeat; VD3, vitamin D 3 ; PARP, poly (ADP-ribose) polymerase; TGFb RII, transforming growth factor receptor II; TGFb DNR II, dominant-negative TGFb receptor 2; siRNA, small interfering RNA; DOX, doxycycline; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PI, propidium iodide; s.d., standard deviation.
